Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Axsome Therapeutics, Inc. (NASDAQ:AXSM) and Neurocrine Biosciences, Inc.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 3,818,037 | $643,472,716 | -23% | 0.22% |
| 2. | Renaissance Technologies Jim Simons | 2,335,897 | $393,680,402 | -4% | 0.54% |
| 3. | Vestal Point Capital Ryan Wilder | 1,880,000 | $316,845,800 | +51% | 7.4% |
| 4. | GLG Partners Noam Gottesman | 601,019 | $101,292,738 | +45% | 0.16% |
| 5. | Armistice Capital Steven Boyd | 535,838 | $90,307,457 | -26% | 1.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | $132,796.50 | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | $5,955.00 | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | $36,921.00 | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | $21,768.30 | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | $249,779.13 | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $157.45 | 826 | $130,050.56 | 8,722 | 2026-09-14 | Filing | |
| $157.20 | 2,311 | $363,284.81 | 42,808 | 2026-09-14 | Filing | |
| $154.61 | 2,154 | $333,029.94 | 64,408 | 2026-09-09 | Filing | |
| $182.01 | 1,250 | $227,507.50 | 1,588 | 2026-07-28 | Filing | |
| $181.02 | 4,367 | $790,514.34 | 16,225 | 2026-07-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 434,881 | $61,683,525 | 0.14% | |
| 2. | 170,802 | $24,226,556 | 7.13% | |
| 3. | 145,818 | $20,682,825 | 0.02% | |
| 4. | 120,842 | $17,140,229 | 0.11% | |
| 5. | 116,370 | $16,505,921 | 0.09% |
News See All
Neurocrine's (NBIX) Data Deluge Reshapes A Familiar Growth Story
On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician's scale says they moved less.
Measuring the Beat: 57 Stocks Surpassing Earnings Expectations
Academic research has consistently found that corporate earnings surprises cluster around small positive values, rather than large outperformance.
Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks
In this article, we will highlight Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks.
10 High Growth NASDAQ Stocks to Buy Now
In this article, we will discuss the 10 High Growth NASDAQ Stocks to Buy Now.
10 High Growth Stocks to Buy Right Now
In this article, we will discuss the 10 High Growth Stocks to Buy Right Now.
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now?
Is NBIX a good stock to buy? We came across a bullish thesis on Neurocrine Biosciences, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on NBIX.
15 Most Promising Stocks to Buy Right Now
In this article, we will look at the 15 Most Promising Stocks to Buy Right Now.
15 High Growth Stocks to Buy and Hold for the Next Decade
In this article, we will look at the 15 High Growth Stocks to Buy and Hold for the Next Decade.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2026 Earnings Call Transcript May 5, 2026Neurocrine Biosciences, Inc. beats earnings expectations. Reported EPS is $1.91, expectations were $1.68.
Hedge Fund Resource Center